Cargando…
The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
BACKGROUND: Biologic disease-modifying antirheumatic drugs (bDMARDs) are important options for managing rheumatoid arthritis (RA). Once patients achieve disease control, clinicians may consider dose reduction or withdrawal of the bDMARD. Results from published studies indicate that some patients wil...
Autores principales: | Tanaka, Yoshiya, Smolen, Josef S., Jones, Heather, Szumski, Annette, Marshall, Lisa, Emery, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610967/ https://www.ncbi.nlm.nih.gov/pubmed/31277720 http://dx.doi.org/10.1186/s13075-019-1937-4 |
Ejemplares similares
-
Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
por: Smolen, Josef S., et al.
Publicado: (2018) -
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021) -
Sustained Remission in Rheumatoid Arthritis: Time to Withdraw Treatment?
por: Sungur, Can M.
Publicado: (2021) -
Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020) -
Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)